Tumor Board Tuesday and Awareness of Novel Therapies and Toxicities in Solid Tumor Oncology

Johnathan Ebben, MD, PhD1,2; Alison Rothbaum2; Rachel Riechelmann, MD, PhD3; Jessica Zanotti, MD3; Michael Pishvaian, MD, PhD2,4

1 University of Wisconsin-Madison Carbone Cancer Center, Madison, WI; 2 Tumor Board Tuesday; 3 AC Camargo, Sao Paulo, Sao Paulo, Brazil; 4 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Abstract ID 11008

Follow us @TumorBoardTues #TumorBoardTuesday

Tumor Board Tuesday (TBT) engages a **global audience** of academic/community oncologists, trainees, patients and patient advocates, accelerating implementation of practice changes

- **82%** of participants became aware of a new therapeutic option, leading to 75% of participants to change a treatment plan based on TBT participation.

**Take messages**

### Anatomy of TBT

- TBT is an oncology learning platform that includes both synchronous and asynchronous elements
- Weekly discussions are led by a topic expert, with a scheduled time of community discussion
- A wrap up summarizes key points and discussion, offering an easy reference to participants

### TBT by the Numbers

**43 cases presented in 2022**
- Breast (18)
- Lung (14)
- GU (11)

### The Impact of TBT

- **Have you become aware of a new treatment strategy through TBT?**
  - Yes: 82%
  - No: 18%
- **Have you/would you change your treatment plan based on a TBT discussion?**
  - Yes: 76%
  - No: 25%

**76.3%** of participants became aware of a new toxicity and/or a new clinical trial that could be an option.

### Conclusions

Evaluation of TBT viewership metrics and CME/voluntary poll responses, reveals that the TBT platform is used by a wide variety of academic and community oncologists, as well as patients and patient advocates, and serves as a valuable tool for disseminating and discussing practice-changing advances and building collaborations.

### Acknowledgements

TBT is immensely grateful to the patients, advocates, discussants and participants that have shaped TBT into a community. We extend our thanks to Integrity Continuing Education for their administrative assistance.

Some TBT sessions are supported by educational grants from Astrazeneca Pharmaceuticals, Daiichi Sankyo Inc, Exelixis, Janssen Biotech Inc., Merck Sharp and Dohme Corp, and Regeneron Pharmaceuticals and Sanofi.
Tumor Board Tuesday and Awareness of Novel Therapies and Toxicities in Solid Tumor Oncology

Johnathan Ebben, MD, PhD\(^1,2\); Alison Rothbaum\(^2\); Rachel Riechelmann, MD, PhD\(^3\); Jéssica Zanotti, MD\(^3\); Michael Pishvaian, MD, PhD\(^2,4\)

\(^1\) University of Wisconsin-Madison Carbone Cancer Center, Madison, WI; \(^2\) Tumor Board Tuesday; \(^3\) AC Camargo, São Paulo, São Paulo, Brazil; \(^4\) Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Abstract ID 11008

Follow us @TumorBoardTues

Anatomy of TBT

Monday: Case Introduction

Tuesday: 8 PM EST discussion led by topic specific experts, knowledge assessments (pre and post discussion)

Synchronous

Asynchronous

Thursday: Case summary including video interview with presenters, graphical abstract
Who Participates in TBT?

- Male: 50%
- Female: 47.4%
- Other/No Disclosure: 2.6%

- Career Development
- Junior/Residents
- Mid
- Senior
- Other

6.216M Impressions
1,961 Tweets
132 Participants
3 Avg Tweets/Hour
15 Avg Tweets/Participant

Twitter data from the #TumorBoardTuesday hashtag from Thu, April 13th 2023, 11:20AM to Sat, May 13th, 2023, 11:20AM (America/New_York) – Symplur.
Have you become aware of a new treatment strategy through TBT?

- Yes: 82%
- No: 18%

Have you/would you change your treatment plan based on a TBT discussion?

- Yes: 75%
- No: 25%

76.3% of participants became aware of a new toxicity and/or a new clinical trial that could be an option.

The TBT platform is accessed and used by oncologists, patients, and patient advocates across practice types, including beyond the United States.

TBT is a valuable tool for disseminating practice changing information and building an online community to advance oncology care.